Tactile Medical Appoints Kristie Burns as Senior Vice President of Marketing & Clinical Affairs
March 15 2021 - 7:30AM
Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:
TCMD), a medical technology company focused on developing medical
devices for the treatment of chronic diseases at home, announced
the appointment of Kristie Burns to the position of Senior Vice
President of Marketing & Clinical Affairs, effective March 22,
2021. Ms. Burns will succeed Darren Wennen, who was promoted from
Vice President of Marketing & Clinical Affairs to Senior Vice
President of Commercial Operations.
“With over 25 years in the healthcare industry, Kristie brings a
wealth of commercial leadership experience in the treatment of
chronic conditions with connected at-home solutions,” said Dan
Reuvers, President and Chief Executive Officer of Tactile Medical.
“Having developed markets with underdiagnosed/undertreated
conditions at both ResMed and Cala Health, I expect her to help
strengthen our market penetration efforts which will lead to more
patients getting the treatment they deserve. I am very pleased to
welcome Kristie to Tactile Medical and look forward to her
contributions as a member of our executive leadership team.”
Prior to joining Tactile Medical, Ms. Burns was the Chief
Marketing Officer at Cala Health, Inc., a privately-held
bioelectronic medicine company developing wearable neuromodulation
therapies for chronic disease. At Cala Health, she organized the
company’s commercial functions and managed the U.S. commercial
introduction of its lead product.
Ms. Burns previously worked for 13 years at ResMed Inc. (NYSE:
RMD) a global leader in digital health and cloud-connected medical
devices focused on sleep apnea and other chronic diseases. She
joined ResMed as a Market Development Manager in 2003 and
subsequently held multiple positions of increasing responsibility
culminating as Vice President of Solutions Marketing for ResMed
Americas. She began her career with a privately-held cardiology
consulting practice that was subsequently acquired by GE Medical
Systems.
“I’m very pleased to join Dan and the team to fuel healthy
growth and the expansion of Tactile Medical,” said Ms. Burns.
“Moreover, I’m excited to continue advancing the impact of at-home
therapies for people living with chronic conditions.”
About Tactile Medical
Tactile Medical is a leader in developing and marketing at-home
therapy devices that treat chronic swelling conditions such as
lymphedema and chronic venous insufficiency. Tactile Medical’s
Mission is to help people suffering from chronic diseases live
better and care for themselves at home. The Company’s unique
offering includes advanced, clinically proven pneumatic compression
devices, as well as continuity of care services provided by a
national network of product specialists and trainers, reimbursement
experts, patient advocates and clinicians. This combination of
products and services ensures that tens of thousands of patients
annually receive the at-home treatment necessary to better manage
their chronic conditions. Tactile Medical takes pride in the fact
that our solutions help increase clinical efficacy, reduce overall
healthcare costs and improve the quality of life for patients with
chronic conditions.
Legal Notice Regarding Forward-Looking
Statements:
This release contains forward-looking
statements. Forward-looking statements are generally identifiable
by the use of words like “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “estimate,” “believe,” “intend,”
“continue,” “confident,” “outlook,” “guidance,” “project,” “goals,”
“look forward,” “poised,” “designed,” “plan,” “return,” “focused,”
“prospects” or “remain” or the negative of these words or other
variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties outside of the Company’s control that can make such
statements untrue, including, but not limited to, the impacts of
the COVID-19 pandemic on the Company’s business, financial
condition and results of operations; the course of the COVID-19
pandemic and its impact on general economic, business and market
conditions; the Company’s inability to execute on its plans to
respond to the COVID-19 pandemic; the adequacy of the Company’s
liquidity to pursue its business objectives; the Company’s ability
to obtain reimbursement from third party payers for its products;
loss or retirement of key executives, including prior to
identifying a successor; adverse economic conditions or intense
competition; loss of a key supplier; entry of new competitors and
products; adverse federal, state and local government regulation;
technological obsolescence of the Company’s products; technical
problems with the Company’s research and products; the Company’s
ability to expand its business through strategic acquisitions; the
Company’s ability to integrate acquisitions and related businesses;
price increases for supplies and components; the effects of current
and future U.S. and foreign trade policy and tariff actions; or the
inability to carry out research, development and commercialization
plans. In addition, other factors that could cause actual results
to differ materially are discussed in the Company’s filings with
the SEC. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company undertakes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Investor Inquiries:
Mike Piccinino, CFA
Managing Director
Westwicke Partners
investorrelations@tactilemedical.com
Tactile Systems Technology (NASDAQ:TCMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tactile Systems Technology (NASDAQ:TCMD)
Historical Stock Chart
From Apr 2023 to Apr 2024